Ocular manifestations of juvenile lupus erythematosus: An 2023 update

• Published in: Acta ophthalmologica (Oxford, England) England), 2024-01, Vol.102 (S279), p.n/a
• Main Authors: Nikolaidou, Anna, Frantzidis, Christos
• Format: Article
• Language: English
• Subjects: Antigen-antibody complexes; Autoantibodies; Blood vessels; Children; Diagnosis; Drug therapy; Epidemiology; Eye diseases; Immunosuppression; Inflammatory diseases; Keratoconjunctivitis; Kidney diseases; Lupus; Meta-analysis; Neuritis; Optic neuritis; Retina; Retinopathy; Reviews; Systemic lupus erythematosus; Vision; Visual pathways; Well being
• ISSN: 1755-375X; 1755-3768
• DOI: 10.1111/aos.16248

Aims/Purpose: Juvenile Systemic Lupus Erythematosus (jSLE) is a chronic multisystem inflammatory disease that manifests before the age of 16 years, following a remitting ‐ relapsing course. The range of clinical presentations of juvenile Systemic Lupus Erythematosus (jSLE) in children is multifaceted. Ocular manifestations are uncommon for children with jSLE but can have a significant effect on their vision if not diagnosed early. Any part of the visual pathway can be affected by jSLE. The aim of this report is to systematically review the ocular manifestations of jSLE. Methods: A systematic review according to Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) 2020 Guidelines was conducted searching MEDLINE and Scopus, including reference lists with appropriate terms for jSLE ocular manifestations. Epidemiological studies, preferably cross‐sectional studies, that describe the prevalence of ocular manifestations in children with a diagnosis or upon diagnosis of jSLE were assessed. Results: Our search yielded 131 results, screened by two independent reviewers. 33 studies were finally included in the review after preliminary assessment. Keratoconjunctivitis sicca, dry eye syndrome, retinopathy and optic neuritis are among the conditions that have been reported. Ocular manifestations in jSLE may be the result of three different mechanisms: the disease itself, infections related to immunosuppression and side effects of drug therapy. Retinal involvement is one of the most important manifestations, implying high possibility of visual loss. It is usually caused by immune complexes and autoantibodies deposition to the retinal vessels or hypertension resulting from kidney disease. Conclusions: Ocular manifestations can occur early in the course of jSLE, sometimes even before other systemic symptoms and can serve as markers of disease activity. Diagnosing ocular manifestations in children with jSLE is important for early intervention, monitoring disease activity, preventing vision loss and providing comprehensive care. By addressing ocular manifestations alongside systemic lupus management, healthcare providers can optimize outcomes and improve the overall well‐being of children with jSLE.